Related Experiment Video
Updated: Aug 24, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
[Management of EGFR mutated non-small cell lung carcinoma patients]
M-P Perquis1, C Tissot1, W Bouleftour1
1Département d'oncologie médicale, Institut de cancérologie Lucien-Newirth, Saint-Priest-en-Jarez, France.
Introduction:
Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC). Over the past decade, the management of NSCLC-carrying EGFR mutation has evolved considerably with the use of tyrosine kinase inhibitors (TKIs). The main objective of this retrospective study was to analyze the evolution of therapeutic strategies in a cohort of patients with metastatic or locally advanced EGFR- mutated NSCLC.
Methods:
Data on patients with EGFR-mutated NSCLC, eligible for TKIs, and treated between 2010 to 2019 were collected. The main therapeutic strategies adopted following progression under TKIs and the prognostic factors for survival were analyzed.
Results:
The median age of the 177 patients was included in the cohort was 70years. The majority of patients (77.4%) received TKIs as first-line treatment, while 16.4% received chemotherapy. Osimertinib initiation as second-line treatment was a factor for better prognosis (OR=0.5). Finally, change of chemotherapy line was the main therapeutic strategy adopted for 41.3% of the patients having relapsed under TKIs.
Discussion:
Therapeutic management of EGFR-mutated NSCLC patients was in accordance with regional, national and international recommendations. The characterization of progression under TKI therapy has become systematic, allowing better adaption of therapeutic strategies.
Insights
Treatment strategies for EGFR-mutated non-small-cell lung cancer (NSCLC) have evolved. Osimertinib as second-line therapy improved prognosis, while chemotherapy changes were common after TKI progression.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Context:
- Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small-cell lung cancer (NSCLC).
- Tyrosine kinase inhibitors (TKIs) have revolutionized NSCLC treatment over the last decade.
- Understanding treatment evolution in EGFR-mutated NSCLC is crucial for optimizing patient outcomes.
Purpose:
- To analyze the evolution of therapeutic strategies in patients with metastatic or locally advanced EGFR-mutated NSCLC.
- To identify prognostic factors for survival in this patient cohort.
- To assess treatment patterns following progression on TKIs.
Summary:
- This retrospective study analyzed 177 patients with EGFR-mutated NSCLC treated between 2010-2019.
- First-line TKIs were used in 77.4% of patients; 16.4% received chemotherapy.
- Osimertinib as second-line therapy was associated with improved prognosis (OR=0.5), and chemotherapy line change was a frequent strategy after TKI progression (41.3%).
Impact:
- Treatment decisions for EGFR-mutated NSCLC align with established guidelines.
- Systematic characterization of progression under TKI therapy enables adaptive treatment strategies.
- This study provides insights into real-world treatment patterns and prognostic factors in EGFR-mutated NSCLC.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...